Published in Infect Immun on April 01, 1992
Staphylococcus aureus capsular polysaccharides. Clin Microbiol Rev (2004) 3.40
Molecular characterization and transcriptional analysis of type 8 capsule genes in Staphylococcus aureus. J Bacteriol (1997) 2.58
Sequence analysis and molecular characterization of genes required for the biosynthesis of type 1 capsular polysaccharide in Staphylococcus aureus. J Bacteriol (1994) 2.54
Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun (1998) 2.29
A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect Immun (1996) 2.13
Effects of in vitro and in vivo growth conditions on expression of type 8 capsular polysaccharide by Staphylococcus aureus. Infect Immun (1993) 1.90
The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. Infect Immun (1997) 1.80
Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect Immun (1993) 1.70
Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect Immun (2005) 1.62
Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect Immun (2001) 1.59
Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun (1997) 1.44
Cloning of type 8 capsule genes and analysis of gene clusters for the production of different capsular polysaccharides in Staphylococcus aureus. J Bacteriol (1996) 1.31
Effects of culture conditions on production of type 5 capsular polysaccharide by human and bovine Staphylococcus aureus strains. Clin Diagn Lab Immunol (1995) 1.21
Availability of complement bound to Staphylococcus aureus to interact with membrane complement receptors influences efficiency of phagocytosis. Infect Immun (2003) 1.18
Genetic analysis of type 5 capsular polysaccharide expression by Staphylococcus aureus. J Bacteriol (1994) 1.16
Further characterization of the epa gene cluster and Epa polysaccharides of Enterococcus faecalis. Infect Immun (2009) 1.16
Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis. Infect Immun (1995) 1.15
Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother (2012) 1.08
Promoter analysis of the cap8 operon, involved in type 8 capsular polysaccharide production in Staphylococcus aureus. J Bacteriol (1999) 1.08
Heterogeneity of cell-associated CP5 expression on Staphylococcus aureus strains demonstrated by flow cytometry. Clin Diagn Lab Immunol (1997) 1.01
Structural and biological characterization of a capsular polysaccharide produced by Staphylococcus haemolyticus. J Bacteriol (2007) 0.98
A non-coding RNA promotes bacterial persistence and decreases virulence by regulating a regulator in Staphylococcus aureus. PLoS Pathog (2014) 0.90
Functional activity of antibodies to the group B polysaccharide of group B streptococci elicited by a polysaccharide-protein conjugate vaccine. Infect Immun (1994) 0.89
Characterization of the structure and biological functions of a capsular polysaccharide produced by Staphylococcus saprophyticus. J Bacteriol (2010) 0.85
Staphylococcus aureus infection after splenectomy and splenic autotransplantation in BALB/c mice. Clin Exp Immunol (2008) 0.79
Epic Immune Battles of History: Neutrophils vs. Staphylococcus aureus. Front Cell Infect Microbiol (2017) 0.75
Encapsulation and capsular types in isolates of Staphylococcus aureus from different sources and relationship to phage types. J Clin Microbiol (1985) 4.88
Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis (1984) 4.10
Determinants of infection in the peritoneal cavity. I. Response to and fate of Staphylococcus aureus and Staphylococcus albus in the mouse. Yale J Biol Med (1962) 3.69
Factors relating to the virulence of staphylococci. I. Comparative studies on two colonial variants. Yale J Biol Med (1962) 3.37
Influence of encapsulation on staphylococcal opsonization and phagocytosis by human polymorphonuclear leukocytes. Infect Immun (1978) 3.23
Serotyping and electron microscopy studies of Staphylococcus aureus clinical isolates with monoclonal antibodies to capsular polysaccharide types 5 and 8. J Clin Microbiol (1987) 3.17
Biological properties of the encapsulated Staphylococcus aureus M. Infect Immun (1974) 2.58
Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect Immun (1988) 2.36
Virulence of Staphylococcus aureus mutants altered in type 5 capsule production. Infect Immun (1991) 2.29
Virulence studies, in mice, of transposon-induced mutants of Staphylococcus aureus differing in capsule size. J Infect Dis (1987) 2.23
Cryptic peptidoglycan and the antiphagocytic effect of the Staphylococcus aureus capsule: model for the antiphagocytic effect of bacterial cell surface polymers. Infect Immun (1979) 2.17
Localization of the third component of complement on the cell wall of encapsulated Staphylococcus aureus M: implications for the mechanism of resistance to phagocytosis. Infect Immun (1979) 2.07
Opsonization of encapsulated Staphylococcus aureus: the role of specific antibody and complement. J Immunol (1982) 2.02
Prevalence of capsular polysaccharide types 5 and 8 among Staphylococcus aureus isolates from cow, goat, and ewe milk. J Clin Microbiol (1988) 1.87
Antibodies to cell wall peptidoglycan of Staphylococcus aureus in patients with serious staphylococcal infections. J Infect Dis (1981) 1.83
Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A. Infect Immun (1990) 1.69
Expression of type 8 capsular polysaccharide and production of toxic shock syndrome toxin 1 are associated among vaginal isolates of Staphylococcus aureus. J Clin Microbiol (1990) 1.54
Reactivity of type-specific monoclonal antibodies with Staphylococcus aureus clinical isolates and purified capsular polysaccharide. Infect Immun (1985) 1.51
Staphylococcus aureus capsular types and antibody response to lung infection in patients with cystic fibrosis. J Clin Microbiol (1988) 1.50
Structural analysis of the cellular constituents of a fresh clinical isolate of Staphylococcus aureus, and their role in the interaction between the organisms and polymorphonuclear leukocytes in the presence of serum factors. Infect Immun (1978) 1.43
Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits. Infect Immun (1987) 1.35
Chemical characterization and immunogenicity of capsular polysaccharide isolated from mucoid Staphylococcus aureus. Infect Immun (1987) 1.22
Capsule production and virulence among strains of Staphylococcus aureus. Ann N Y Acad Sci (1974) 1.21
Diagnosing Staphylococcus aureus endocarditis by detecting antibodies against S. aureus capsular polysaccharide types 5 and 8. J Infect Dis (1991) 1.05
Antibody responses to protein A in patients with Staphylococcus aureus bacteremia and endocarditis. J Clin Microbiol (1990) 0.86
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol (1995) 88.05
Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet (2000) 24.22
The transcriptional program in the response of human fibroblasts to serum. Science (1999) 19.19
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A (1999) 14.16
Evidence for a clonal origin of methicillin resistance in Staphylococcus aureus. Science (1993) 10.09
SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett (1995) 9.62
Molecular epidemiology: application of contemporary techniques to the typing of microorganisms. Clin Infect Dis (1993) 7.60
Persistent colonisation of potable water as a source of Mycobacterium avium infection in AIDS. Lancet (1994) 6.47
Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature (1996) 5.44
Polymersomes: tough vesicles made from diblock copolymers. Science (1999) 4.76
How to select and interpret molecular strain typing methods for epidemiological studies of bacterial infections: a review for healthcare epidemiologists. Molecular Typing Working Group of the Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol (1997) 4.28
Predominance of two newly described capsular polysaccharide types among clinical isolates of Staphylococcus aureus. Diagn Microbiol Infect Dis (1984) 4.10
Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science (1999) 4.08
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem (1998) 3.88
Interstitial cells of Cajal generate a rhythmic pacemaker current. Nat Med (1998) 3.62
Persistent and relapsing infections associated with small-colony variants of Staphylococcus aureus. Clin Infect Dis (1995) 3.49
Preparation of tubulin from brain. Methods Enzymol (1982) 3.39
The stabilization of proteins by sucrose. J Biol Chem (1981) 3.34
Infective endocarditis: an analysis based on strict case definitions. Ann Intern Med (1981) 3.25
Rapid penicillinase paper strip test for detection of beta-lactamase-producing Haemophilus influenzae and Neisseria gonorrhoeae. Antimicrob Agents Chemother (1977) 3.02
Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer (1999) 2.95
Adherence of Candida albicans and other Candida species to mucosal epithelial cells. Infect Immun (1980) 2.91
A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet (1999) 2.88
The association of cancer and the nephrotic syndrome. Ann Intern Med (1966) 2.88
Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res (1999) 2.87
Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther (1989) 2.78
Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum Mol Genet (1997) 2.69
The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J (1996) 2.64
Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther (1996) 2.63
The Staphylococcus aureus allelic genetic loci for serotype 5 and 8 capsule expression contain the type-specific genes flanked by common genes. Microbiology (1997) 2.61
Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell (1994) 2.60
Identification of mitogen-activated protein (MAP) kinase-activated protein kinase-3, a novel substrate of CSBP p38 MAP kinase. J Biol Chem (1996) 2.55
Reversion of the glycopeptide resistance phenotype in Staphylococcus aureus clinical isolates. Antimicrob Agents Chemother (2000) 2.48
Binding sites in Escherichia coli dihydrofolate reductase communicate by modulating the conformational ensemble. Proc Natl Acad Sci U S A (2000) 2.47
Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology (1999) 2.40
Use of alternative techniques of hysterectomy in Ohio, 1988-1994. N Engl J Med (1996) 2.40
Virulence of Staphylococcus aureus mutants altered in type 5 capsule production. Infect Immun (1991) 2.29
Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun (1998) 2.29
Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem (1997) 2.28
Comparison of restriction endonuclease analysis, ribotyping, and pulsed-field gel electrophoresis for molecular differentiation of Clostridium difficile strains. J Clin Microbiol (1994) 2.23
Constitutive production of a unique lymphokine (IL 3) by the WEHI-3 cell line. J Immunol (1982) 2.22
Isolation of Mycobacterium avium complex from water in the United States, Finland, Zaire, and Kenya. J Clin Microbiol (1993) 2.20
Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania. Int J Tuberc Lung Dis (2011) 2.19
Cytolysis induced by human lymphotoxin. Am J Pathol (1972) 2.14
Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket. J Biol Chem (1998) 2.12
Molecular epidemiology of adhesin and hemolysin virulence factors among uropathogenic Escherichia coli. Infect Immun (1989) 2.12
Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol (2000) 2.11
Epidemiologic and clinical utility of typing systems for differentiating among strains of methicillin-resistant Staphylococcus aureus. Infect Control Hosp Epidemiol (1991) 2.09
Characterization of Candida albicans adherence to human vaginal epithelial cells in vitro. Infect Immun (1983) 2.07
Application of fluorescence energy transfer and polarization to monitor Escherichia coli cAMP receptor protein and lac promoter interaction. Proc Natl Acad Sci U S A (1990) 2.05
Partial specific volumes and interactions with solvent components of proteins in guanidine hydrochloride. Biochemistry (1974) 2.03
The reconstitution of microtubules from purified calf brain tubulin. Biochemistry (1975) 2.02
In vitro reconstitution of calf brain microtubules: effects of solution variables. Biochemistry (1977) 1.99
Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun (1997) 1.99
A new nomenclature for the cytoplasmic ribosomal proteins of Saccharomyces cerevisiae. Nucleic Acids Res (1997) 1.99
Clonal relationships among bloodstream isolates of Escherichia coli. Infect Immun (1995) 1.95
Restriction fragment length polymorphisms among uropathogenic Escherichia coli isolates: pap-related sequences compared with rrn operons. Infect Immun (1990) 1.95
The kinetics of interleukin 1 secretion from activated monocytes. Differences between interleukin 1 alpha and interleukin 1 beta. J Biol Chem (1988) 1.95
Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. Circulation (1999) 1.93
Bacterial adhesins and host factors: role in the development and outcome of Escherichia coli bacteremia. Clin Infect Dis (1993) 1.92
Integration of synthetic globin genes into an E. coli plasmid. Nucleic Acids Res (1976) 1.85
Clinical and molecular epidemiology of sporadic and clustered cases of nosocomial Clostridium difficile diarrhea. Am J Med (1996) 1.84
Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res (1999) 1.82
Establishment of continuous cultures of thy1.2+, Lyt1+, 2-T cells with purified interleukin 3. Cell (1981) 1.80
Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun (1999) 1.80
The role of staphylococcal polysaccharide microcapsule expression in septicemia and septic arthritis. Infect Immun (1997) 1.80
SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am J Physiol Lung Cell Mol Physiol (2000) 1.75
Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Biol Chem (1996) 1.74
Polyclonal infections due to Mycobacterium avium complex in patients with AIDS detected by pulsed-field gel electrophoresis of sequential clinical isolates. J Clin Microbiol (1994) 1.73
Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis. Arthritis Rheum (2000) 1.72
Development and characterization of a Staphylococcus aureus nasal colonization model in mice. Infect Immun (1999) 1.69
Adherence of Staphylococcus aureus to endothelial cells: influence of capsular polysaccharide, global regulator agr, and bacterial growth phase. Infect Immun (2000) 1.68
The chemical characterization of calf brain microtubule protein subunits. J Biol Chem (1973) 1.65
Phyloproteomics: species identification of Enterobacteriaceae using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. J Mol Microbiol Biotechnol (2001) 1.65
Staphylococcus aureus microcapsule expression attenuates bacterial virulence in a rat model of experimental endocarditis. J Infect Dis (1992) 1.64
Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides. Proc Natl Acad Sci U S A (2001) 1.64
Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol (1997) 1.64
Extracellular signal-regulated kinase plays an essential role in hypertrophic agonists, endothelin-1 and phenylephrine-induced cardiomyocyte hypertrophy. J Biol Chem (2000) 1.60
Capsule production and growth phase influence binding of complement to Staphylococcus aureus. Infect Immun (2001) 1.59
Effectiveness of a continuous quality improvement program aiming to reduce unplanned extubation: a prospective study. Intensive Care Med (1996) 1.58
Identification of ribosomal protein autoantigens. J Immunol (1985) 1.57
Inhibition of lymphocyte mitogenesis by immobilized antigen-antibody complexes. J Exp Med (1975) 1.55
AA.AG@helix.ends: A:A and A:G base-pairs at the ends of 16 S and 23 S rRNA helices. J Mol Biol (2001) 1.54
Expression of type 8 capsular polysaccharide and production of toxic shock syndrome toxin 1 are associated among vaginal isolates of Staphylococcus aureus. J Clin Microbiol (1990) 1.54
Pelvic support defects and visceral and sexual function in women treated with sacrospinous ligament suspension and pelvic reconstruction. Am J Obstet Gynecol (1996) 1.54
Laryngeal chemosensitivity: a possible mechanism for sudden infant death. Pediatrics (1975) 1.54
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemia. J Pharmacol Exp Ther (2001) 1.54
Relationship between indole production and differentiation of Klebsiella species: indole-positive and -negative isolates of Klebsiella determined to be clonal. J Clin Microbiol (1993) 1.53
The effect of acute hypoxia and hypercapnia on the ultrastructure of the central nervous system. Brain (1968) 1.52
Preferential solvent interactions between proteins and polyethylene glycols. J Biol Chem (1981) 1.52
Reactivity of type-specific monoclonal antibodies with Staphylococcus aureus clinical isolates and purified capsular polysaccharide. Infect Immun (1985) 1.51
Macrophage apoptosis in mycobacterial infections. J Leukoc Biol (1999) 1.51
Rapid diagnosis of gram-negative bacterial meningitis by the Limulus endotoxin assay. J Clin Microbiol (1978) 1.51
The fine structure, potassium content, and respiratory activity of isolated rat liver parenchymal cells prepared by improved enzymatic techniques. J Cell Biol (1973) 1.49
Characterization of Glu126 and Arg144, two residues that are indispensable for substrate binding in the lactose permease of Escherichia coli. Biochemistry (1999) 1.47